½ÃÀ庸°í¼­
»óǰÄÚµå
1337630

¼¼°èÀÇ ÀǾàǰ ¹«±Õ ½ÃÇè ½ÃÀå ±Ô¸ð ¹× Á¡À¯À² ºÐ¼® : À¯Çüº°, Á¦Ç° À¯Çüº°, ½ÃÇè À¯Çüº°, ¿ëµµº°, ÃÖÁ¾»ç¿ëÀÚº° - »ê¾÷ ¼ö¿ä ¿¹Ãø(-2030³â)

Pharmaceutical Sterility Testing Market Size and Share Analysis Report by Type, Product Type, Test Type, Application, End User - Global Industry Demand Forecast to 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Prescient & Strategic Intelligence | ÆäÀÌÁö Á¤º¸: ¿µ¹® 190 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°è ÀǾàǰ ¹«±Õ ½ÃÇè ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 29¾ï 5,390¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2023-2030³â ¼ºÀå·üÀº 11.2%¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ´Â »ý¸í°øÇÐ ¹× Á¦¾à ±â¾÷ÀÇ ¹ßÀü, ¿¬±¸ °³¹ß Ȱµ¿ÀÇ Áõ°¡, Áúº´ ¹ß»ý·ü Áõ°¡, ÀÇ·á »ê¾÷¿¡ ´ëÇÑ Á¤ºÎÀÇ ¸·´ëÇÑ ÁöÃâ¿¡ ±âÀÎÇÕ´Ï´Ù.

ÇØÃæÀ¸·Î ÀÎÇÑ Áúº´ ¹ß»ýÀÌ Áõ°¡ÇÔ¿¡ µû¶ó È¿°úÀûÀÌ°í ¾ÈÀüÇÑ Ä¡·áÁ¦¸¦ »ý»êÇϱâ À§ÇÑ ¿¬±¸°³¹ß Ȱµ¿ÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, COVID-19¿Í °°Àº ½É°¢ÇÑ ¹ÙÀÌ·¯½º °¨¿°ÁõÀ» ¿¹¹æÇϱâ À§ÇÑ ¿¬±¸¿Í È¿°úÀûÀÌ°í ¾ÈÀüÇÑ ¹é½Å °³¹ßÀ» Áß½ÉÀ¸·Î ÇÑ ¿¬±¸°¡ °è¼ÓµÇ°í ÀÖ´Â °Íµµ »ê¾÷¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù.

Ç÷¾× ¾Ç¼ºÁ¾¾ç ¹ß»ýÀÌ Áõ°¡Çϰí ÀÖÀ¸¸ç, Leukemia & Lymphoma Society¿¡ µû¸£¸é ¹Ì±¹¿¡¼­´Â 3¸í Áß 1¸íÀÌ ¹éÇ÷º´, °ñ¼öÁ¾, ¸²ÇÁÁ¾¿¡ °É·È´Ù°í ÇÕ´Ï´Ù. À¯ÀüÀÚ Ä¡·á¿Í ¸é¿ª¼¼Æ÷ Ä¡·á¿Í °°Àº ¹ÙÀÌ¿ÀÀǾàǰÀº Ç÷¾×¾ÏÀÇ ´ëü Ä¡·á¹ýÀ¸·Î ºü¸£°Ô ¹Þ¾Æµé¿©Áö°í ÀÖ½À´Ï´Ù. ÀÌ´Â ÀÌ·¯ÇÑ Ä¡·áÁ¦°¡ ÀÌ·¯ÇÑ Á¾·ùÀÇ Áúº´¿¡ ´ëÇØ ³ôÀº È¿´É°ú È¿´ÉÀ» °¡Áö°í Àֱ⠶§¹®ÀÔ´Ï´Ù.

2022³â±îÁö ¾Æ¿ô¼Ò½Ì ºÎ¹®ÀÌ 60%ÀÇ Á¡À¯À²·Î ¾÷°è¸¦ ÁÖµµÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ´Â ¾Æ¿ô¼Ò½ÌÀÌ Áß¼Ò±Ô¸ðÀÇ Á¦¾àȸ»ç¿¡ À¯¸®Çϱ⠶§¹®¿¡ ³Î¸® º¸±ÞµÇ°í Àֱ⠶§¹®ÀÔ´Ï´Ù.

¶ÇÇÑ, ¾Æ¿ô¼Ò½ÌÀº Á¦¾àȸ»ç¿¡°Ô Ä¡·á Àü¹®¼º°ú ¾÷¹« È¿À²¼ºÀ» ³ôÀ̰í, ¿Âµð¸Çµå ¼­ºñ½º¸¦ ½±°Ô ÀÌ¿ëÇÒ ¼ö ÀÖÀ¸¸ç, Áö¸®Àû ÀÔÁö¸¦ Çâ»ó½ÃŰ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù.

¶ÇÇÑ, ¸¹Àº Áß¼Ò±â¾÷Àº ¾çÁúÀÇ ¹«±Õ ½ÃÇè ¿ä°ÇÀ» ÃæÁ·½Ãų ¼ö ÀÖ´Â ÃæºÐÇÑ ÀÚ¿øÀÌ ¾ø±â ¶§¹®¿¡ FDAÀÇ ±ÔÁ¤À» Åë°úÇϱâ À§ÇØ ¾Æ¿ô¼Ò½ÌÀ» ¿ä±¸Çϰí ÀÖ½À´Ï´Ù.

ºÏ¹Ì ½ÃÀåÀº 2022³â 40%ÀÇ Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ÀÌ´Â ÁÖ¿ä Á¦¾à ¹× ¹ÙÀÌ¿À Á¦¾à ±â¾÷ÀÇ Á¸Àç, »ý¸í°øÇÐ »ê¾÷ ¹× Á¦¾à »ê¾÷ÀÇ R&D Ȱµ¿ Áõ°¡, Á¦Ç° µµÀÔ Áõ°¡, ¸¸¼º ÁúȯÀÇ ³ôÀº ¹ß»ý·ü, R&D ½Ã¼³ ¼³¸³¿¡ ´ëÇÑ Á¤ºÎ Áö¿ø Á¤Ã¥ µîÀÌ ¿øÀÎÀ¸·Î ²ÅÈü´Ï´Ù.

¶ÇÇÑ °­·ÂÇÑ ÀÇ·á Á¤Ã¥ÀÇ Á¸Àç, ¾ö°ÝÇÑ ÀǾàǰ ½ÂÀÎ Çʿ伺, ÀǾàǰ ¾ÈÀü¿¡ ´ëÇÑ ÀÏ¹Ý ´ëÁßÀÇ ÀÎ½Ä Áõ°¡, ÷´Ü ±â¼ú ¼ö¿ë Áõ°¡, ¿©·¯ Á¾·ùÀÇ Ç÷¾× ¾Ç¼º Á¾¾ç Ä¡·á¸¦ À§ÇÑ À¯ÀüÀÚ Ä¡·á ¹× ¼¼Æ÷ Ä¡·á Ãâ½Ã µîÀÌ ÀÌ Áö¿ªÀÇ »ê¾÷ ¹ßÀü¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

¶ÇÇÑ À¯·´Àº ºÏ¹Ì¿¡ ÀÌ¾î µÎ ¹øÂ°·Î ³ôÀº ¸ÅÃâ Á¡À¯À²À» º¸À̰í ÀÖ½À´Ï´Ù. ÀÌ´Â ÀÌ Áö¿ªÀÇ ¸¹Àº ±¹°¡¿¡¼­ º¸ÆíÀû ÀǷẸÇèÁ¦µµ°¡ Çü¼ºµÇ¾î ÀÇ·áÁ¦Ç°¿¡ ´ëÇÑ ¼ö¿ä°¡ Å©°Ô Áõ°¡Ç߱⠶§¹®ÀÔ´Ï´Ù. ÀǾàǰ ¾ÈÀü¿¡ ´ëÇÑ ¾ö°ÝÇÑ ±ÔÁ¦ Á¤Ã¥À» äÅÃÇÏ´Â °Íµµ »ê¾÷ ¼ºÀå¿¡ ±â¿©ÇÏ´Â ÁÖ¿ä ¿äÀÎÀÔ´Ï´Ù.

µðÁöÅÐ Ç÷§ÆûÀÇ ¼ö¿ë È®´ë´Â ÀǾàǰ ¹«±Õ ½ÃÇè ¼ö¿ä¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖÀ¸¸ç, ÀÌ·¯ÇÑ Ãß¼¼´Â ÇâÈÄ ¸î ³â µ¿¾È Áö¼ÓµÉ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

ÀÌ º¸°í¼­´Â ¼¼°è ÀǾàǰ ¹«±Õ ½ÃÇè ½ÃÀå¿¡ ´ëÇÑ Á¶»ç ºÐ¼®°ú ÇÔ²² ½ÃÀå ¿ªÇÐ, Áö¿ªº° ½ÃÀå ¸ÅÃâ, °æÀï »óȲ µîÀÇ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹üÀ§

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ¾÷°è Àü¹®°¡/KOLÀÇ ¼Ò¸®

Á¦5Àå ½ÃÀå ÁöÇ¥

Á¦6Àå »ê¾÷ Àü¸Á

  • ½ÃÀå ¿ªÇÐ
    • µ¿Çâ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ/°úÁ¦
    • ¼ºÀå ÃËÁø¿äÀÎ/¾ïÁ¦¿äÀÎÀÇ ¿µÇ⠺м®
  • COVID-19ÀÇ ¿µÇâ
  • Porter's Five Forces ºÐ¼®

Á¦7Àå ¼¼°è ½ÃÀå

  • °³¿ä
  • ½ÃÀå ¸ÅÃâ : À¯Çüº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : Á¦Ç° À¯Çüº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : ½ÃÇè À¯Çüº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : ¿ëµµº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : ÃÖÁ¾»ç¿ëÀÚº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : Áö¿ªº°(2017-2030³â)

Á¦8Àå ºÏ¹Ì ½ÃÀå

  • °³¿ä
  • ½ÃÀå ¸ÅÃâ : À¯Çüº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : Á¦Ç° À¯Çüº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : ½ÃÇè À¯Çüº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : ¿ëµµº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : ÃÖÁ¾»ç¿ëÀÚº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : ±¹°¡º°(2017-2030³â)

Á¦9Àå À¯·´ ½ÃÀå

  • °³¿ä
  • ½ÃÀå ¸ÅÃâ : À¯Çüº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : Á¦Ç° À¯Çüº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : ½ÃÇè À¯Çüº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : ¿ëµµº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : ÃÖÁ¾»ç¿ëÀÚº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : ±¹°¡º°(2017-2030³â)

Á¦10Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

  • °³¿ä
  • ½ÃÀå ¸ÅÃâ : À¯Çüº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : Á¦Ç° À¯Çüº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : ½ÃÇè À¯Çüº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : ¿ëµµº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : ÃÖÁ¾»ç¿ëÀÚº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : ±¹°¡º°(2017-2030³â)

Á¦11Àå Áß³²¹Ì ½ÃÀå

  • °³¿ä
  • ½ÃÀå ¸ÅÃâ : À¯Çüº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : Á¦Ç° À¯Çüº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : ½ÃÇè À¯Çüº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : ¿ëµµº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : ÃÖÁ¾»ç¿ëÀÚº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : ±¹°¡º°(2017-2030³â)

Á¦12Àå Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« ½ÃÀå

  • °³¿ä
  • ½ÃÀå ¸ÅÃâ : À¯Çüº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : Á¦Ç° À¯Çüº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : ½ÃÇè À¯Çüº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : ¿ëµµº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : ÃÖÁ¾»ç¿ëÀÚº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : ±¹°¡º°(2017-2030³â)

Á¦13Àå ¹Ì±¹ ½ÃÀå

  • °³¿ä
  • ½ÃÀå ¸ÅÃâ : À¯Çüº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : Á¦Ç° À¯Çüº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : ½ÃÇè À¯Çüº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : ¿ëµµº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : ÃÖÁ¾»ç¿ëÀÚº°(2017-2030³â)

Á¦14Àå ij³ª´Ù ½ÃÀå

  • °³¿ä
  • ½ÃÀå ¸ÅÃâ : À¯Çüº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : Á¦Ç° À¯Çüº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : ½ÃÇè À¯Çüº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : ¿ëµµº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : ÃÖÁ¾»ç¿ëÀÚº°(2017-2030³â)

Á¦15Àå µ¶ÀÏ ½ÃÀå

  • °³¿ä
  • ½ÃÀå ¸ÅÃâ : À¯Çüº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : Á¦Ç° À¯Çüº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : ½ÃÇè À¯Çüº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : ¿ëµµº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : ÃÖÁ¾»ç¿ëÀÚº°(2017-2030³â)

Á¦16Àå ÇÁ¶û½º ½ÃÀå

  • °³¿ä
  • ½ÃÀå ¸ÅÃâ : À¯Çüº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : Á¦Ç° À¯Çüº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : ½ÃÇè À¯Çüº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : ¿ëµµº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : ÃÖÁ¾»ç¿ëÀÚº°(2017-2030³â)

Á¦17Àå ¿µ±¹ ½ÃÀå

  • °³¿ä
  • ½ÃÀå ¸ÅÃâ : À¯Çüº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : Á¦Ç° À¯Çüº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : ½ÃÇè À¯Çüº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : ¿ëµµº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : ÃÖÁ¾»ç¿ëÀÚº°(2017-2030³â)

Á¦18Àå ÀÌÅ»¸®¾Æ ½ÃÀå

  • °³¿ä
  • ½ÃÀå ¸ÅÃâ : À¯Çüº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : Á¦Ç° À¯Çüº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : ½ÃÇè À¯Çüº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : ¿ëµµº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : ÃÖÁ¾»ç¿ëÀÚº°(2017-2030³â)

Á¦19Àå ½ºÆäÀÎ ½ÃÀå

  • °³¿ä
  • ½ÃÀå ¸ÅÃâ : À¯Çüº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : Á¦Ç° À¯Çüº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : ½ÃÇè À¯Çüº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : ¿ëµµº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : ÃÖÁ¾»ç¿ëÀÚº°(2017-2030³â)

Á¦20Àå ÀϺ» ½ÃÀå

  • °³¿ä
  • ½ÃÀå ¸ÅÃâ : À¯Çüº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : Á¦Ç° À¯Çüº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : ½ÃÇè À¯Çüº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : ¿ëµµº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : ÃÖÁ¾»ç¿ëÀÚº°(2017-2030³â)

Á¦21Àå Áß±¹ ½ÃÀå

  • °³¿ä
  • ½ÃÀå ¸ÅÃâ : À¯Çüº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : Á¦Ç° À¯Çüº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : ½ÃÇè À¯Çüº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : ¿ëµµº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : ÃÖÁ¾»ç¿ëÀÚº°(2017-2030³â)

Á¦22Àå Àεµ ½ÃÀå

  • °³¿ä
  • ½ÃÀå ¸ÅÃâ : À¯Çüº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : Á¦Ç° À¯Çüº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : ½ÃÇè À¯Çüº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : ¿ëµµº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : ÃÖÁ¾»ç¿ëÀÚº°(2017-2030³â)

Á¦23Àå È£ÁÖ ½ÃÀå

  • °³¿ä
  • ½ÃÀå ¸ÅÃâ : À¯Çüº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : Á¦Ç° À¯Çüº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : ½ÃÇè À¯Çüº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : ¿ëµµº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : ÃÖÁ¾»ç¿ëÀÚº°(2017-2030³â)

Á¦24Àå Çѱ¹ ½ÃÀå

  • °³¿ä
  • ½ÃÀå ¸ÅÃâ : À¯Çüº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : Á¦Ç° À¯Çüº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : ½ÃÇè À¯Çüº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : ¿ëµµº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : ÃÖÁ¾»ç¿ëÀÚº°(2017-2030³â)

Á¦25Àå ºê¶óÁú ½ÃÀå

  • °³¿ä
  • ½ÃÀå ¸ÅÃâ : À¯Çüº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : Á¦Ç° À¯Çüº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : ½ÃÇè À¯Çüº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : ¿ëµµº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : ÃÖÁ¾»ç¿ëÀÚº°(2017-2030³â)

Á¦26Àå ¸ß½ÃÄÚ ½ÃÀå

  • °³¿ä
  • ½ÃÀå ¸ÅÃâ : À¯Çüº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : Á¦Ç° À¯Çüº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : ½ÃÇè À¯Çüº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : ¿ëµµº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : ÃÖÁ¾»ç¿ëÀÚº°(2017-2030³â)

Á¦27Àå »ç¿ìµð¾Æ¶óºñ¾Æ ½ÃÀå

  • °³¿ä
  • ½ÃÀå ¸ÅÃâ : À¯Çüº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : Á¦Ç° À¯Çüº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : ½ÃÇè À¯Çüº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : ¿ëµµº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : ÃÖÁ¾»ç¿ëÀÚº°(2017-2030³â)

Á¦28Àå ³²¾ÆÇÁ¸®Ä«°øÈ­±¹ ½ÃÀå

  • °³¿ä
  • ½ÃÀå ¸ÅÃâ : À¯Çüº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : Á¦Ç° À¯Çüº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : ½ÃÇè À¯Çüº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : ¿ëµµº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : ÃÖÁ¾»ç¿ëÀÚº°(2017-2030³â)

Á¦29Àå ¾Æ¶ø¿¡¹Ì¸®Æ® ½ÃÀå

  • °³¿ä
  • ½ÃÀå ¸ÅÃâ : À¯Çüº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : Á¦Ç° À¯Çüº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : ½ÃÇè À¯Çüº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : ¿ëµµº°(2017-2030³â)
  • ½ÃÀå ¸ÅÃâ : ÃÖÁ¾»ç¿ëÀÚº°(2017-2030³â)

Á¦30Àå °æÀï »óȲ

  • ½ÃÀå ÁøÃâ ±â¾÷°ú ±× Á¦°øÇ° ¸®½ºÆ®
  • ÁÖ¿ä ±â¾÷ÀÇ °æÀï º¥Ä¡¸¶Å·
  • ÁÖ¿ä ±â¾÷ÀÇ Á¦Ç° º¥Ä¡¸¶Å·
  • ÃÖ±ÙÀÇ Àü·«Àû ¹ßÀü

Á¦31Àå ±â¾÷ °³¿ä

  • Steris plc
  • Boston Analytical
  • Sartorius AG
  • Arbro Pharmaceuticals Private Limited & Auriga Research Private Limited
  • Lucideon Limited
  • Pace Analytical Life Sciences, LLC
  • SGS SA
  • Sotera Health Company
  • Merck KGaA
  • Pall Corporation
  • Charles River Laboratories International, Inc
  • Thermo Fisher Scientific Inc
  • Almac Group Limited
  • Pacific BioLabs
  • BIOMERIEUX S.A.

Á¦32Àå ºÎ·Ï

ksm 23.09.06

The pharmaceutical sterility testing market will reach USD 2,953.9 million by 2030, growing at a rate of 11.2% during 2023-2030. This is because of the development of biotech and pharma firms, an increase in their R&D activities, an increase in the incidence of diseases, and substantial government spending on the healthcare industry.

The increasing occurrence of diseases in the pest has brought about an increase in R&D activities for the manufacturing of effective and safe therapeutics. Regarding this, the continuing studies on the preventing severe viral infections, such as the novel coronavirus, and those centered on the expansion of effective and safe vaccines have a positive impact on the industry.

The occurrence of hematological malignancies is increasing. As per the Leukemia & Lymphoma Society, every 3 minutes, a person is identified with leukemia, myeloma, or lymphoma in the U.S. Biopharma, for example gene, and immune cell therapies are quickly being accepted as a substitute treatment for hematological cancers. This is due to the fact that such therapeutics have high effectiveness and efficacy against these kinds of diseases.

The outsourcing category led the industry, with a 60% share, in 2022. This is due to the fact that outsourcing is becoming popular among small and medium-sized pharma firms because of the advantages provided to them.

Furthermore, for pharma firms, outsourcing surges therapeutic expertise and working efficiency, makes on demand services accessible, and assists in the development of their geographical presence.

Moreover, many small and medium-sized companies do not have the satisfactory resources for fulfilling their requirements for quality sterility testing and, consequently, desire outsourcing to pass FDA rules.

North America pharmaceutical sterility testing market had a major share of 40%, in 2022. This is credited to the presence of leading pharma and biopharma players, increasing R&D activities in the biotech and pharma industry, increasing number of product introductions, high occurrence of chronic ailments, and supportive policies of the government for the setup of R&D facilities.

Furthermore, the existence of strong healthcare policies, strict drug approval needs, increasing public consciousness of drug safety, increasing acceptance of pioneering technologies, and the launch of gene and cell therapies for treating more than a few hematologic malignancies are resultant in the development of the regional industry.

Furthermore, Europe follows North America in terms of revenue share. This is attributable to the formation of universal public healthcare systems in numerous nations in the region, which has considerably increased the requirement for healthcare products. The employment of stringent regulatory policies with regards to the safety of drugs is another key factor contributing to the growth of the industry.

The increasing acceptance of digital platforms has a positive impact on the demand for pharmaceutical sterility testing, and this will be the trend in the years to come as well.

Table of Contents

Chapter 1. Research Scope

  • 1.1. Research Objectives
  • 1.2. Market Definition
  • 1.3. Analysis Period
  • 1.4. Market Size Breakdown by Segments
    • 1.4.1. Market size breakdown, by type
    • 1.4.2. Market size breakdown, by product type
    • 1.4.3. Market size breakdown, by test type
    • 1.4.4. Market size breakdown, by application
    • 1.4.5. Market size breakdown, by end user
    • 1.4.6. Market size breakdown, by region
    • 1.4.7. Market size breakdown, by country
  • 1.5. Market Data Reporting Unit
    • 1.5.1. Value
  • 1.6. Key Stakeholders

Chapter 2. Research Methodology

  • 2.1. Secondary Research
    • 2.1.1. Paid
    • 2.1.2. Unpaid
    • 2.1.3. P&S Intelligence database
  • 2.2. Primary Research
  • 2.3. Market Size Estimation
  • 2.4. Data Triangulation
  • 2.5. Currency Conversion Rates
  • 2.6. Assumptions for the Study
  • 2.7. Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Voice of Industry Experts/KOLs

Chapter 5. Market Indicators

Chapter 6. Industry Outlook

  • 6.1. Market Dynamics
    • 6.1.1. Trends
    • 6.1.2. Drivers
    • 6.1.3. Restraints/challenges
    • 6.1.4. Impact analysis of drivers/restraints
  • 6.2. Impact of COVID-19
  • 6.3. Porter's Five Forces Analysis
    • 6.3.1. Bargaining power of buyers
    • 6.3.2. Bargaining power of suppliers
    • 6.3.3. Threat of new entrants
    • 6.3.4. Intensity of rivalry
    • 6.3.5. Threat of substitutes

Chapter 7. Global Market

  • 7.1. Overview
  • 7.2. Market Revenue, by Type (2017-2030)
  • 7.3. Market Revenue, by Product type (2017-2030)
  • 7.4. Market Revenue, by Test type (2017-2030)
  • 7.5. Market Revenue, by Application (2017-2030)
  • 7.6. Market Revenue, by End user (2017-2030)
  • 7.7. Market Revenue, by Region (2017-2030)

Chapter 8. North America Market

  • 8.1. Overview
  • 8.2. Market Revenue, by Type (2017-2030)
  • 8.3. Market Revenue, by Product type (2017-2030)
  • 8.4. Market Revenue, by Test type (2017-2030)
  • 8.5. Market Revenue, by Application (2017-2030)
  • 8.6. Market Revenue, by End user (2017-2030)
  • 8.7. Market Revenue, by Country (2017-2030)

Chapter 9. Europe Market

  • 9.1. Overview
  • 9.2. Market Revenue, by Type (2017-2030)
  • 9.3. Market Revenue, by Product type (2017-2030)
  • 9.4. Market Revenue, by Test type (2017-2030)
  • 9.5. Market Revenue, by Application (2017-2030)
  • 9.6. Market Revenue, by End user (2017-2030)
  • 9.7. Market Revenue, by Country (2017-2030)

Chapter 10. APAC Market

  • 10.1. Overview
  • 10.2. Market Revenue, by Type (2017-2030)
  • 10.3. Market Revenue, by Product type (2017-2030)
  • 10.4. Market Revenue, by Test type (2017-2030)
  • 10.5. Market Revenue, by Application (2017-2030)
  • 10.6. Market Revenue, by End user (2017-2030)
  • 10.7. Market Revenue, by Country (2017-2030)

Chapter 11. LATAM Market

  • 11.1. Overview
  • 11.2. Market Revenue, by Type (2017-2030)
  • 11.3. Market Revenue, by Product type (2017-2030)
  • 11.4. Market Revenue, by Test type (2017-2030)
  • 11.5. Market Revenue, by Application (2017-2030)
  • 11.6. Market Revenue, by End user (2017-2030)
  • 11.7. Market Revenue, by Country (2017-2030)

Chapter 12. MEA Market

  • 12.1. Overview
  • 12.2. Market Revenue, by Type (2017-2030)
  • 12.3. Market Revenue, by Product type (2017-2030)
  • 12.4. Market Revenue, by Test type (2017-2030)
  • 12.5. Market Revenue, by Application (2017-2030)
  • 12.6. Market Revenue, by End user (2017-2030)
  • 12.7. Market Revenue, by Country (2017-2030)

Chapter 13. U.S. Market

  • 13.1. Overview
  • 13.2. Market Revenue, by Type (2017-2030)
  • 13.3. Market Revenue, by Product type (2017-2030)
  • 13.4. Market Revenue, by Test type (2017-2030)
  • 13.5. Market Revenue, by Application (2017-2030)
  • 13.6. Market Revenue, by End user (2017-2030)

Chapter 14. Canada Market

  • 14.1. Overview
  • 14.2. Market Revenue, by Type (2017-2030)
  • 14.3. Market Revenue, by Product type (2017-2030)
  • 14.4. Market Revenue, by Test type (2017-2030)
  • 14.5. Market Revenue, by Application (2017-2030)
  • 14.6. Market Revenue, by End user (2017-2030)

Chapter 15. Germany Market

  • 15.1. Overview
  • 15.2. Market Revenue, by Type (2017-2030)
  • 15.3. Market Revenue, by Product type (2017-2030)
  • 15.4. Market Revenue, by Test type (2017-2030)
  • 15.5. Market Revenue, by Application (2017-2030)
  • 15.6. Market Revenue, by End user (2017-2030)

Chapter 16. France Market

  • 16.1. Overview
  • 16.2. Market Revenue, by Type (2017-2030)
  • 16.3. Market Revenue, by Product type (2017-2030)
  • 16.4. Market Revenue, by Test type (2017-2030)
  • 16.5. Market Revenue, by Application (2017-2030)
  • 16.6. Market Revenue, by End user (2017-2030)

Chapter 17. U.K. Market

  • 17.1. Overview
  • 17.2. Market Revenue, by Type (2017-2030)
  • 17.3. Market Revenue, by Product type (2017-2030)
  • 17.4. Market Revenue, by Test type (2017-2030)
  • 17.5. Market Revenue, by Application (2017-2030)
  • 17.6. Market Revenue, by End user (2017-2030)

Chapter 18. Italy Market

  • 18.1. Overview
  • 18.2. Market Revenue, by Type (2017-2030)
  • 18.3. Market Revenue, by Product type (2017-2030)
  • 18.4. Market Revenue, by Test type (2017-2030)
  • 18.5. Market Revenue, by Application (2017-2030)
  • 18.6. Market Revenue, by End user (2017-2030)

Chapter 19. Spain Market

  • 19.1. Overview
  • 19.2. Market Revenue, by Type (2017-2030)
  • 19.3. Market Revenue, by Product type (2017-2030)
  • 19.4. Market Revenue, by Test type (2017-2030)
  • 19.5. Market Revenue, by Application (2017-2030)
  • 19.6. Market Revenue, by End user (2017-2030)

Chapter 20. Japan Market

  • 20.1. Overview
  • 20.2. Market Revenue, by Type (2017-2030)
  • 20.3. Market Revenue, by Product type (2017-2030)
  • 20.4. Market Revenue, by Test type (2017-2030)
  • 20.5. Market Revenue, by Application (2017-2030)
  • 20.6. Market Revenue, by End user (2017-2030)

Chapter 21. China Market

  • 21.1. Overview
  • 21.2. Market Revenue, by Type (2017-2030)
  • 21.3. Market Revenue, by Product type (2017-2030)
  • 21.4. Market Revenue, by Test type (2017-2030)
  • 21.5. Market Revenue, by Application (2017-2030)
  • 21.6. Market Revenue, by End user (2017-2030)

Chapter 22. India Market

  • 22.1. Overview
  • 22.2. Market Revenue, by Type (2017-2030)
  • 22.3. Market Revenue, by Product type (2017-2030)
  • 22.4. Market Revenue, by Test type (2017-2030)
  • 22.5. Market Revenue, by Application (2017-2030)
  • 22.6. Market Revenue, by End user (2017-2030)

Chapter 23. Australia Market

  • 23.1. Overview
  • 23.2. Market Revenue, by Type (2017-2030)
  • 23.3. Market Revenue, by Product type (2017-2030)
  • 23.4. Market Revenue, by Test type (2017-2030)
  • 23.5. Market Revenue, by Application (2017-2030)
  • 23.6. Market Revenue, by End user (2017-2030)

Chapter 24. South Korea Market

  • 24.1. Overview
  • 24.2. Market Revenue, by Type (2017-2030)
  • 24.3. Market Revenue, by Product type (2017-2030)
  • 24.4. Market Revenue, by Test type (2017-2030)
  • 24.5. Market Revenue, by Application (2017-2030)
  • 24.6. Market Revenue, by End user (2017-2030)

Chapter 25. Brazil Market

  • 25.1. Overview
  • 25.2. Market Revenue, by Type (2017-2030)
  • 25.3. Market Revenue, by Product type (2017-2030)
  • 25.4. Market Revenue, by Test type (2017-2030)
  • 25.5. Market Revenue, by Application (2017-2030)
  • 25.6. Market Revenue, by End user (2017-2030)

Chapter 26. Mexico Market

  • 26.1. Overview
  • 26.2. Market Revenue, by Type (2017-2030)
  • 26.3. Market Revenue, by Product type (2017-2030)
  • 26.4. Market Revenue, by Test type (2017-2030)
  • 26.5. Market Revenue, by Application (2017-2030)
  • 26.6. Market Revenue, by End user (2017-2030)

Chapter 27. Saudi Arabia Market

  • 27.1. Overview
  • 27.2. Market Revenue, by Type (2017-2030)
  • 27.3. Market Revenue, by Product type (2017-2030)
  • 27.4. Market Revenue, by Test type (2017-2030)
  • 27.5. Market Revenue, by Application (2017-2030)
  • 27.6. Market Revenue, by End user (2017-2030)

Chapter 28. South Africa Market

  • 28.1. Overview
  • 28.2. Market Revenue, by Type (2017-2030)
  • 28.3. Market Revenue, by Product type (2017-2030)
  • 28.4. Market Revenue, by Test type (2017-2030)
  • 28.5. Market Revenue, by Application (2017-2030)
  • 28.6. Market Revenue, by End user (2017-2030)

Chapter 29. U.A.E. Market

  • 29.1. Overview
  • 29.2. Market Revenue, by Type (2017-2030)
  • 29.3. Market Revenue, by Product type (2017-2030)
  • 29.4. Market Revenue, by Test type (2017-2030)
  • 29.5. Market Revenue, by Application (2017-2030)
  • 29.6. Market Revenue, by End user (2017-2030)

Chapter 30. Competitive Landscape

  • 30.1. List of Market Players and their Offerings
  • 30.2. Competitive Benchmarking of Key Players
  • 30.3. Product Benchmarking of Key Players
  • 30.4. Recent Strategic Developments

Chapter 31. Company Profiles

  • 31.1. Steris plc
    • 31.1.1. Business overview
    • 31.1.2. Product and service offerings
    • 31.1.3. Key financial summary
  • 31.2. Boston Analytical
    • 31.2.1. Business overview
    • 31.2.2. Product and service offerings
  • 31.3. Sartorius AG
    • 31.3.1. Business overview
    • 31.3.2. Product and service offerings
  • 31.4. Arbro Pharmaceuticals Private Limited & Auriga Research Private Limited
    • 31.4.1. Business overview
    • 31.4.2. Product and service offerings
  • 31.5. Lucideon Limited
    • 31.5.1. Business overview
    • 31.5.2. Product and service offerings
  • 31.6. Pace Analytical Life Sciences, LLC
    • 31.6.1. Business overview
    • 31.6.2. Product and service offerings
  • 31.7. SGS SA
    • 31.7.1. Business overview
    • 31.7.2. Product and service offerings
    • 31.7.3. Key financial summary
  • 31.8. Sotera Health Company
    • 31.8.1. Business overview
    • 31.8.2. Product and service offerings
    • 31.8.3. Key financial summary
  • 31.9. Merck KGaA
    • 31.9.1. Business overview
    • 31.9.2. Product and service offerings
    • 31.9.3. Key financial summary
  • 31.10. Pall Corporation
    • 31.10.1. Business overview
    • 31.10.2. Product and service offerings
  • 31.11. Charles River Laboratories International, Inc
    • 31.11.1. Business overview
    • 31.11.2. Product and service offerings
    • 31.11.3. Key financial summary
  • 31.12. Thermo Fisher Scientific Inc
    • 31.12.1. Business overview
    • 31.12.2. Product and service offerings
    • 31.12.3. Key financial summary
  • 31.13. Almac Group Limited
    • 31.13.1. Business overview
    • 31.13.2. Product and service offerings
  • 31.14. Pacific BioLabs
    • 31.14.1. Business overview
    • 31.14.2. Product and service offerings
  • 31.15. BIOMERIEUX S.A.
    • 31.15.1. Business overview
    • 31.15.2. Product and service offerings
    • 31.15.3. Key financial summary

Chapter 32. Appendix

  • 32.1. Abbreviations
  • 32.2. Sources and References
  • 32.3. Related Reports
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦